SLC5A2 and diabetic kidney disease: SGLT2 inhibitors also reduce the risk of new-onset diabetic nephropathy, slow the rate of kidney function decline, and reduced the risk of major kidney events (Heerspink et al. 2020; Neal et al. 2017a; Wanner et al. 2016).